Pub Date : 2018-07-26DOI: 10.6000/1927-7229.2018.07.03.3
T. Shrihari
Endorphins are endogenous morphine, neuropeptides produced from pituitary gland in response to stress and pain. These are of three types- beta-endorphins, dynorphins, enkephalins, binds to mu, kappa, delta receptors found on immune cells and nervous system. Beta-endorphins is the most abundant endorphin synthesized and stored in the anterior pituitary gland. It has got various activities such as Immune stimulatory activity, anti-inflammatory activity, analgesic activity, stress buster, and anti-aging activity. Immune stimulatory activity by activation of NK cells, macrophages, T-lymphocytes, anti-inflammatory activity by production of cytokines, such as IL-18, 1L-10, analgesic activity by inhibiting substance-p, anti-ageing by suppressing ROS, RNS, free radicals and lengthening telomeres, stress buster activity by decreasing cortisol and nor-adrenaline, dopamine release involved in holistic, preventive, promotive, therapeutic and palliative treatment of cancer without any adverse affects and inexpensive. This article brief’s about the current concept of novel actions of endorphins in holistic treatment of cancer .
{"title":"Endorphins – A Novel Holistic Therapeutic Approach to Cancer","authors":"T. Shrihari","doi":"10.6000/1927-7229.2018.07.03.3","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.03.3","url":null,"abstract":"Endorphins are endogenous morphine, neuropeptides produced from pituitary gland in response to stress and pain. These are of three types- beta-endorphins, dynorphins, enkephalins, binds to mu, kappa, delta receptors found on immune cells and nervous system. Beta-endorphins is the most abundant endorphin synthesized and stored in the anterior pituitary gland. It has got various activities such as Immune stimulatory activity, anti-inflammatory activity, analgesic activity, stress buster, and anti-aging activity. Immune stimulatory activity by activation of NK cells, macrophages, T-lymphocytes, anti-inflammatory activity by production of cytokines, such as IL-18, 1L-10, analgesic activity by inhibiting substance-p, anti-ageing by suppressing ROS, RNS, free radicals and lengthening telomeres, stress buster activity by decreasing cortisol and nor-adrenaline, dopamine release involved in holistic, preventive, promotive, therapeutic and palliative treatment of cancer without any adverse affects and inexpensive. This article brief’s about the current concept of novel actions of endorphins in holistic treatment of cancer .","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90365509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-17DOI: 10.6000/1927-7229.2018.07.02.4
T. Shrihari
Inflammation is the physiological response to an injury, it could be chemical, thermal, physical and infectious for reparative activity to injury. Recent data suggest that chronic inflammation leads to cancer development. Inflammatory mediators released to surrounding environment due to inflammation by inflammatory cells acts as a defensive or offensive depends on secretion of chemical mediators of inflammation such as growth factors, cytokines activating various transcriptional pathways bring about cell proliferation, angiogenesis further leads to tumor growth. This article describe the role of inflammatory cells and its mediators to development of cancer, various underlying unanswered future challenge questions in association with inflammation and cancer.
{"title":"Inflammation and Cancer: Critical View","authors":"T. Shrihari","doi":"10.6000/1927-7229.2018.07.02.4","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.02.4","url":null,"abstract":"Inflammation is the physiological response to an injury, it could be chemical, thermal, physical and infectious for reparative activity to injury. Recent data suggest that chronic inflammation leads to cancer development. Inflammatory mediators released to surrounding environment due to inflammation by inflammatory cells acts as a defensive or offensive depends on secretion of chemical mediators of inflammation such as growth factors, cytokines activating various transcriptional pathways bring about cell proliferation, angiogenesis further leads to tumor growth. This article describe the role of inflammatory cells and its mediators to development of cancer, various underlying unanswered future challenge questions in association with inflammation and cancer.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"15 1","pages":"32-36"},"PeriodicalIF":0.0,"publicationDate":"2018-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80845665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-17DOI: 10.6000/1927-7229.2018.07.02.1
Adilson Domingos dos Reis Filho, F. Frajacomo, R. C. V. Junior, Haracelli Christina Barbosa Alves Leite da Costa, J. Navalta, R. Tibana, J. Prestes, F. Voltarelli, Brazil Mt
Head and neck cancer (HNC) is one of the most common types of the disease, particularly among men, and is characterized by a high incidence of death. Among the non-pharmacological factors that help in survival and improving quality of life is physical exercise, especially strength training. The purpose of this short communication was to briefly review the literature and present a training proposal for oncology patients with HNC. Evidence is provided that physical exercise, mainly short-term strength (HIIT [High-Intensity Interval Training]) and aerobic training, contributes to increased expectation and quality of life in cancer survivors. After reviewing the current state of literature, we conclude that strength training, by providing maintenance of muscle mass, improves the autonomy and quality of life of oncology patients with HNC.
{"title":"Neurochemistry of Neurochemicals: Messengers of Brain FunctionsStrength Training as an Adjunct to the Maintenance of Muscle Mass in Patients with Head and Neck Cancer","authors":"Adilson Domingos dos Reis Filho, F. Frajacomo, R. C. V. Junior, Haracelli Christina Barbosa Alves Leite da Costa, J. Navalta, R. Tibana, J. Prestes, F. Voltarelli, Brazil Mt","doi":"10.6000/1927-7229.2018.07.02.1","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.02.1","url":null,"abstract":"Head and neck cancer (HNC) is one of the most common types of the disease, particularly among men, and is characterized by a high incidence of death. Among the non-pharmacological factors that help in survival and improving quality of life is physical exercise, especially strength training. The purpose of this short communication was to briefly review the literature and present a training proposal for oncology patients with HNC. Evidence is provided that physical exercise, mainly short-term strength (HIIT [High-Intensity Interval Training]) and aerobic training, contributes to increased expectation and quality of life in cancer survivors. After reviewing the current state of literature, we conclude that strength training, by providing maintenance of muscle mass, improves the autonomy and quality of life of oncology patients with HNC.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"8 1","pages":"22-24"},"PeriodicalIF":0.0,"publicationDate":"2018-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82382336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-17DOI: 10.6000/1927-7229.2018.07.02.2
T. Shrihari
Myeloid derived suppressor cells (MDSC) are specialized immunoregulatorycells and major cause of immunosuppression in oral cancer tumor microenvironment. Which are generated by various mediators of chronic inflammation. MDSC exerts its effects by two mechanisms, first is enzymatic mechanism by two enzymes which are elevated in MDSC are arginaseand iNOS2, second is non-enzymatic mechanism by ROS, peroxynitrate ,L-selectin and interaction with other immune cells. It also has a role in progression of oral cancer by secreting inflammatory mediators. This article brief about the MDSC in immune regulation and tumor progression in oral cancer tumor microenvironment.
{"title":"Myeloid Derived Suppressor Cells in Oral Cancer: An Emerging Concept","authors":"T. Shrihari","doi":"10.6000/1927-7229.2018.07.02.2","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.02.2","url":null,"abstract":"Myeloid derived suppressor cells (MDSC) are specialized immunoregulatorycells and major cause of immunosuppression in oral cancer tumor microenvironment. Which are generated by various mediators of chronic inflammation. MDSC exerts its effects by two mechanisms, first is enzymatic mechanism by two enzymes which are elevated in MDSC are arginaseand iNOS2, second is non-enzymatic mechanism by ROS, peroxynitrate ,L-selectin and interaction with other immune cells. It also has a role in progression of oral cancer by secreting inflammatory mediators. This article brief about the MDSC in immune regulation and tumor progression in oral cancer tumor microenvironment.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"10 1","pages":"25-28"},"PeriodicalIF":0.0,"publicationDate":"2018-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86231805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-17DOI: 10.6000/1927-7229.2018.07.02.3
A. Sharifpour, Siavash Abedi, M. Aliyali, Sepideh Safa Navai, A. Davoodi, S. Hashemi
Deep vein thrombosis (DVT) is a common disease that can lead to death. Many studies have looked at the chance of occurrence and the factors affecting thrombosis as one of the complications of cancer. This chance increases in patients with more severe cancer. The progression of cancer and the risk of death in patients with DVT is more severe and with a worse prognosis. But according to our knowledge, there is no accurate report of the incidence and diagnosis of cancer long after thrombosis .In our case, lung adenocarcinoma arose months after the onset of frequent thrombosis in a healthy person. So recommended to consider the risk of developing cancer in patients with recurrent thrombosis.
{"title":"Incidence of Lung Adenocarcinoma following Recurrent Deep Vein Thrombosis: A Case Presentation","authors":"A. Sharifpour, Siavash Abedi, M. Aliyali, Sepideh Safa Navai, A. Davoodi, S. Hashemi","doi":"10.6000/1927-7229.2018.07.02.3","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.02.3","url":null,"abstract":"Deep vein thrombosis (DVT) is a common disease that can lead to death. Many studies have looked at the chance of occurrence and the factors affecting thrombosis as one of the complications of cancer. This chance increases in patients with more severe cancer. The progression of cancer and the risk of death in patients with DVT is more severe and with a worse prognosis. But according to our knowledge, there is no accurate report of the incidence and diagnosis of cancer long after thrombosis .In our case, lung adenocarcinoma arose months after the onset of frequent thrombosis in a healthy person. So recommended to consider the risk of developing cancer in patients with recurrent thrombosis.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"26 1","pages":"29-31"},"PeriodicalIF":0.0,"publicationDate":"2018-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80580791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-16DOI: 10.6000/1927-7229.2018.07.01.3
L. Cole
Objectives : Two forms of hCG are produced, the hormone hCG binding a luteinizing hormone/hCG joint receptor and the autocrine hyperglycosylated hCG binding a TGF-AŸ receptor. In pregnancy, hyperglycosylated hCG drives placental cell growth and invasion in implantation of pregnancy. It also blocks apoptosis. Human cancer cells steal the hCG AŸ-subunit gene and use hyperglycosylated hCG and its AŸ-subunit to drive malignancy. Here we examine research into hyperglycosylated hCG and its AŸ-subunit, and show that these molecules drive malignancy in most or possibly all human cancers. Methods : Mouse monoclonal antibody B152was raised against intact hyperglycosylated hCG, batch C5. The antibody binds hyperglycosylated hCG and its AŸ-subunit but does not bind the hormone hCG or its subunits. Total hCG was measured using the Siemens Immulite hCG assay, hyperglycosylated hCG and its AŸ-subunit were measured using the antibody B152 assay. Results : Eight independent center show that the hCG AŸ-subunit produced by cancers promotes malignancy, enhances cancer cell growth, cancer cell invasion and blockage of apoptosis in cancers. A study of 42 choriocarcinoma cases shows that percentage hyperglycosylated hCG exactly correlates with weekly doubling rate of cancer. It is concluded that hyperglycosylated hCG drive malignancy in this cancer. In a study with 7 separate cancers it is shown that increasing concentrations of hyperglycosylated hCG enhance all cancers. Increasing concentration of monoclonal antibody B152. Hyperglycosylated hCG and its AŸ-subunit drives cancer growth, cancer invasion and blocks apoptosis in cancer cells. Antibody B152 suppressed cancer cell growth creating a non-malignant-like state (no growth, no invasion), with no cancer growth over a starting 70% confluency. Conclusions : Choriocarcinoma is an example of cancer driven in malignancy by hyperglycosylated hCG, cancer aggression (weekly doubling rate) exactly correlating with percent hyperglycosylated hCG. In examining cancers, antibody B152 suppresses malignancy totally halting cancer growth in 7 of 7 cancer. This confirms that only the antigens, hyperglycosylated hCG and its AŸ-subunit drives malignancy in cancer cases.
{"title":"Hyperglycosylated hCG Drives Malignancy in Most or All Human Cancers: Tying All Research Together","authors":"L. Cole","doi":"10.6000/1927-7229.2018.07.01.3","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.01.3","url":null,"abstract":"Objectives : Two forms of hCG are produced, the hormone hCG binding a luteinizing hormone/hCG joint receptor and the autocrine hyperglycosylated hCG binding a TGF-AŸ receptor. In pregnancy, hyperglycosylated hCG drives placental cell growth and invasion in implantation of pregnancy. It also blocks apoptosis. Human cancer cells steal the hCG AŸ-subunit gene and use hyperglycosylated hCG and its AŸ-subunit to drive malignancy. Here we examine research into hyperglycosylated hCG and its AŸ-subunit, and show that these molecules drive malignancy in most or possibly all human cancers. Methods : Mouse monoclonal antibody B152was raised against intact hyperglycosylated hCG, batch C5. The antibody binds hyperglycosylated hCG and its AŸ-subunit but does not bind the hormone hCG or its subunits. Total hCG was measured using the Siemens Immulite hCG assay, hyperglycosylated hCG and its AŸ-subunit were measured using the antibody B152 assay. Results : Eight independent center show that the hCG AŸ-subunit produced by cancers promotes malignancy, enhances cancer cell growth, cancer cell invasion and blockage of apoptosis in cancers. A study of 42 choriocarcinoma cases shows that percentage hyperglycosylated hCG exactly correlates with weekly doubling rate of cancer. It is concluded that hyperglycosylated hCG drive malignancy in this cancer. In a study with 7 separate cancers it is shown that increasing concentrations of hyperglycosylated hCG enhance all cancers. Increasing concentration of monoclonal antibody B152. Hyperglycosylated hCG and its AŸ-subunit drives cancer growth, cancer invasion and blocks apoptosis in cancer cells. Antibody B152 suppressed cancer cell growth creating a non-malignant-like state (no growth, no invasion), with no cancer growth over a starting 70% confluency. Conclusions : Choriocarcinoma is an example of cancer driven in malignancy by hyperglycosylated hCG, cancer aggression (weekly doubling rate) exactly correlating with percent hyperglycosylated hCG. In examining cancers, antibody B152 suppresses malignancy totally halting cancer growth in 7 of 7 cancer. This confirms that only the antigens, hyperglycosylated hCG and its AŸ-subunit drives malignancy in cancer cases.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"34 1","pages":"14-21"},"PeriodicalIF":0.0,"publicationDate":"2018-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90446745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-28DOI: 10.6000/1927-7229.2018.07.01.1
A. Berroukche, Ely Mohamed-Amine, Mohamed Terras, M. Slimani
: Prostate cancer (Pca) is a common neoplasia in elderly men. Its incidence increased over the last two decades in the Northern Africa. This study aimed to perform a comparison between epidemiological profiles of Pca in patients from two Maghreb countries (Algeria and Mauritania). This is a retrospective study carried out during 2014- 2016, on population of 124 cases including 64 Pca Algerian patients recorded in the Oncology Department of Saida hospital, the Urology Department of Oran University Hospital and 60 Pca Mauritanians patients recruited in the National Oncology Center and the Friendship Hospital in Nouakchott. For these Pca patiens of different ethnic origin, demographic characteristics were studied and biological monitoring of the tumor marker PSA (prostate specific antigen) was performed in medical biological analysis laboratories using the same methods of serum-PSA assay. The mean age was significantly different in both groups of Pca Algerian and Mauritanian patients (respectively 74 vs 70 years). No significant positive correlation between the age and the PSA, in both groups, was recorded (R = 0.00796 vs R = 0.127) ( p ˃ 0.05 ). The mean serum- PSA levels were 156.5 ± 76.4 ( Pca Algerians) and 179.3 ± 52.1 ng / mL (Pca Mauritanians). Histological evidence was obtained in 54.6 % (Pca Algerians) and 23.3 % (Pca Mauritanian patients). 15 Pca Patients with metastatic tumor stage and 17 cases of death were found. Prostate cancer essentially affects men old over 50 years in both Northern African countries and this comparative study showed the same methods of screening, diagnosis and therapeutic treatment of Pca used in these two areas.
前列腺癌(Pca)是老年男性常见的肿瘤。在过去二十年中，其发病率在北非有所增加。本研究旨在比较来自两个马格里布国家(阿尔及利亚和毛里塔尼亚)的Pca患者的流行病学概况。这是一项2014- 2016年对124例患者进行的回顾性研究，其中包括Saida医院肿瘤科、Oran大学医院泌尿外科记录的64例阿尔及利亚Pca患者，以及在努瓦克肖特国家肿瘤中心和友谊医院招募的60例毛里塔尼亚Pca患者。对这些不同种族的前列腺癌患者进行人口统计学特征研究，并在医学生物分析实验室采用与血清PSA检测相同的方法进行肿瘤标志物PSA(前列腺特异性抗原)的生物监测。阿尔及利亚和毛里塔尼亚两组Pca患者的平均年龄有显著差异(分别为74岁和70岁)。两组患者年龄与PSA无显著正相关(R = 0.00796 vs R = 0.127) (p < 0.05)。平均血清PSA水平阿尔及利亚Pca为156.5±76.4 ng / mL，毛里塔尼亚Pca为179.3±52.1 ng / mL。54.6%(阿尔及利亚Pca患者)和23.3%(毛里塔尼亚Pca患者)获得组织学证据。15例Pca患者转移期，17例死亡。在这两个北非国家，前列腺癌主要影响50岁以上的男性，这项比较研究显示，这两个地区使用的前列腺癌筛查、诊断和治疗方法相同。
{"title":"Comparative Epidemiological Profiles in Prostate Cancer Algerian and Mauritanian Patients: Retrospective Study of 124 Cases","authors":"A. Berroukche, Ely Mohamed-Amine, Mohamed Terras, M. Slimani","doi":"10.6000/1927-7229.2018.07.01.1","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.01.1","url":null,"abstract":": Prostate cancer (Pca) is a common neoplasia in elderly men. Its incidence increased over the last two decades in the Northern Africa. This study aimed to perform a comparison between epidemiological profiles of Pca in patients from two Maghreb countries (Algeria and Mauritania). This is a retrospective study carried out during 2014- 2016, on population of 124 cases including 64 Pca Algerian patients recorded in the Oncology Department of Saida hospital, the Urology Department of Oran University Hospital and 60 Pca Mauritanians patients recruited in the National Oncology Center and the Friendship Hospital in Nouakchott. For these Pca patiens of different ethnic origin, demographic characteristics were studied and biological monitoring of the tumor marker PSA (prostate specific antigen) was performed in medical biological analysis laboratories using the same methods of serum-PSA assay. The mean age was significantly different in both groups of Pca Algerian and Mauritanian patients (respectively 74 vs 70 years). No significant positive correlation between the age and the PSA, in both groups, was recorded (R = 0.00796 vs R = 0.127) ( p ˃ 0.05 ). The mean serum- PSA levels were 156.5 ± 76.4 ( Pca Algerians) and 179.3 ± 52.1 ng / mL (Pca Mauritanians). Histological evidence was obtained in 54.6 % (Pca Algerians) and 23.3 % (Pca Mauritanian patients). 15 Pca Patients with metastatic tumor stage and 17 cases of death were found. Prostate cancer essentially affects men old over 50 years in both Northern African countries and this comparative study showed the same methods of screening, diagnosis and therapeutic treatment of Pca used in these two areas.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"19 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88936714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-28DOI: 10.6000/1927-7229.2018.07.01.2
M. Değer, V. Izol, F. Gokalp, Y. Bayazıt, I. Aridogan, Z. Tansug
Objective : In this study, we investigated the concordance between Gleason scores of transrectal ultrasound guided biopsy and radical prostatectomy specimens in patients diagnosed with prostate cancer via transrectal ultrasound guided biopsy and treated with radical prostatectomy in our clinic. Material and Method : 115 patients were included in our study treated with radical prostatectomy for organ-confined prostate cancer between the dates of November 2011 and December 2014. Data of these patients are reviewed retrospectively. Results : The average age of the patients was 61.8 ± 6.8 (43-76) years. The average body mass index of these patients were (BMI) 26.7 ± 3.34 (19.3 – 35.3) kg/m². Average PSA value was 6.6 ± 10.1 (1.4 – 80) ng/ml. Gleason scores of transrectal ultrasound guided biopsy and radical prostatectomy were observed concordant in 74 (64.3%) of 115 patients, while 41 (35.6%) were not concordant. Gleason score was decreased by 1 grade for 8.6% (10 patients) of patients, it was increased by 1 for 26.0% (30 patients) of patients and for 0.8% (1 patient) it was increased by 3. Discussion : These findings indicate indicate that Gleason scores of transrectal ultrasound guided biopsy and prostatectomy specimens may be discordant.
{"title":"Evaluation of Concordance between Gleason Scores of Tansrectal Ultrasound Guided Biopsy and Radical Prostatectomy Samples in Prostate Cancer","authors":"M. Değer, V. Izol, F. Gokalp, Y. Bayazıt, I. Aridogan, Z. Tansug","doi":"10.6000/1927-7229.2018.07.01.2","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.01.2","url":null,"abstract":"Objective : In this study, we investigated the concordance between Gleason scores of transrectal ultrasound guided biopsy and radical prostatectomy specimens in patients diagnosed with prostate cancer via transrectal ultrasound guided biopsy and treated with radical prostatectomy in our clinic. Material and Method : 115 patients were included in our study treated with radical prostatectomy for organ-confined prostate cancer between the dates of November 2011 and December 2014. Data of these patients are reviewed retrospectively. Results : The average age of the patients was 61.8 ± 6.8 (43-76) years. The average body mass index of these patients were (BMI) 26.7 ± 3.34 (19.3 – 35.3) kg/m². Average PSA value was 6.6 ± 10.1 (1.4 – 80) ng/ml. Gleason scores of transrectal ultrasound guided biopsy and radical prostatectomy were observed concordant in 74 (64.3%) of 115 patients, while 41 (35.6%) were not concordant. Gleason score was decreased by 1 grade for 8.6% (10 patients) of patients, it was increased by 1 for 26.0% (30 patients) of patients and for 0.8% (1 patient) it was increased by 3. Discussion : These findings indicate indicate that Gleason scores of transrectal ultrasound guided biopsy and prostatectomy specimens may be discordant.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"13 1","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73136424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-14DOI: 10.6000/1927-7229.2017.06.04.2
K. Anna, Chadha D. Vijayta
Abstract: With the innovations in nuclear medicine techniques, Lutetium 177 ( 177 Lu) has epitomized as a revolutionary theranostic agent- with both scintigraphic and therapeutic properties. The present review focusses on the introduction of 177 Lu as a promising modality for tumor diagnosis and therapy in widespread metastases . Being a shorter I²-range emitter providing better irradiation of smaller tumor volumes, 177 Lu- based PRRT is being increasingly used in patients with somatostatin receptor positive neuroendocrine tumors. Clinical trials with 177 Lu–DOTATATE and 177 Lu–DOTATOC have gained considerable interest in recent years with successful tumor regression in patients with malignant metastatic neuroendocrine tumors. Especially, therapy with 177 Lu-DOTATATE PRRT has reported to significantly improve the quality of life of Gastroenteropancreatic NET patients because of higher affinity of DOTATATE for the somatostatin type 2 receptors. In addition, this review also sheds light on the diagnostic and palliative aspects of 177 Lu which also serves to be an attractive candidate for the preparation of radiopharmaceuticals for radiation synovectomy of small to medium sized joints. Enlisting all the said features, 177 Lu is strongly emerging as a promising theranostic agent that could possibly endow Nuclear Medicine an edge over other conventional therapies in near future.
摘要:随着核医学技术的不断创新，Lutetium 177 (177 Lu)已成为一种具有科学和治疗双重特性的革命性治疗药物。目前的综述重点是介绍177 - Lu作为一种有前途的肿瘤诊断和治疗广泛转移的模式。177 Lu- based PRRT是一种较短的I²范围发射器，可以更好地照射较小的肿瘤体积，越来越多地用于生长抑素受体阳性的神经内分泌肿瘤患者。近年来，177 lu -“DOTATATE”和177 lu -“DOTATOC”的临床试验在恶性转移性神经内分泌肿瘤患者的肿瘤消退中获得了相当大的兴趣。特别是177 Lu-DOTATATE PRRT治疗有报道称，由于DOTATATE对生长抑素2型受体有更高的亲和力，可以显著改善胃肠胰网患者的生活质量。此外，本综述还揭示了177 Lu在诊断和姑息治疗方面的作用，也为中小关节放射滑膜切除术的放射性药物的制备提供了一个有吸引力的候选者。具有上述所有特征，177 Lu作为一种有前景的治疗药物正在强势崛起，可能在不久的将来赋予核医学比其他传统疗法更大的优势。
{"title":"Emerging Role of 177Lu in Nuclear Oncology: A Brief Review","authors":"K. Anna, Chadha D. Vijayta","doi":"10.6000/1927-7229.2017.06.04.2","DOIUrl":"https://doi.org/10.6000/1927-7229.2017.06.04.2","url":null,"abstract":"Abstract: With the innovations in nuclear medicine techniques, Lutetium 177 ( 177 Lu) has epitomized as a revolutionary theranostic agent- with both scintigraphic and therapeutic properties. The present review focusses on the introduction of 177 Lu as a promising modality for tumor diagnosis and therapy in widespread metastases . Being a shorter I²-range emitter providing better irradiation of smaller tumor volumes, 177 Lu- based PRRT is being increasingly used in patients with somatostatin receptor positive neuroendocrine tumors. Clinical trials with 177 Lu–DOTATATE and 177 Lu–DOTATOC have gained considerable interest in recent years with successful tumor regression in patients with malignant metastatic neuroendocrine tumors. Especially, therapy with 177 Lu-DOTATATE PRRT has reported to significantly improve the quality of life of Gastroenteropancreatic NET patients because of higher affinity of DOTATATE for the somatostatin type 2 receptors. In addition, this review also sheds light on the diagnostic and palliative aspects of 177 Lu which also serves to be an attractive candidate for the preparation of radiopharmaceuticals for radiation synovectomy of small to medium sized joints. Enlisting all the said features, 177 Lu is strongly emerging as a promising theranostic agent that could possibly endow Nuclear Medicine an edge over other conventional therapies in near future.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"25 1","pages":"148-153"},"PeriodicalIF":0.0,"publicationDate":"2017-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89755796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-14DOI: 10.6000/1927-7229.2017.06.04.3
Megha Jain, V. Jain, A. Gupta, S. Saawarn, S. Khan
Abstract: Background : Hormones have been recognized as regulator of the cell growth, differentiation and maturation. It has become increasingly evident that hormone may play a crucial role in the genesis and progression of several cancers like those of breast, ovary, testis, thyroid, prostrate including oral cancer. Aim : Present overview aims to discuss and provide data on possible role of various hormones including stress hormone, sex hormone, parathyroid and related hormone protein, melatonin and active metabolite of vitamin D3 in causation and progression of Oral squamous cell carcinoma (OSCC). Data Acquisition : A systematic search of existing literature was carried out for the keywords like hormones and cancer, hormones and oral cancer or OSCC utilizing the Google, Google Scholar and PubMed databases for extraction, assortment and compilation of data. Inference : In conclusion, we found that hormones are directly or indirectly involved in the pathogenesis of the OSCC and can be utilized in its management and prevention.
{"title":"Role of Hormones in Oral Squamous Cell Carcinoma - An Update","authors":"Megha Jain, V. Jain, A. Gupta, S. Saawarn, S. Khan","doi":"10.6000/1927-7229.2017.06.04.3","DOIUrl":"https://doi.org/10.6000/1927-7229.2017.06.04.3","url":null,"abstract":"Abstract: Background : Hormones have been recognized as regulator of the cell growth, differentiation and maturation. It has become increasingly evident that hormone may play a crucial role in the genesis and progression of several cancers like those of breast, ovary, testis, thyroid, prostrate including oral cancer. Aim : Present overview aims to discuss and provide data on possible role of various hormones including stress hormone, sex hormone, parathyroid and related hormone protein, melatonin and active metabolite of vitamin D3 in causation and progression of Oral squamous cell carcinoma (OSCC). Data Acquisition : A systematic search of existing literature was carried out for the keywords like hormones and cancer, hormones and oral cancer or OSCC utilizing the Google, Google Scholar and PubMed databases for extraction, assortment and compilation of data. Inference : In conclusion, we found that hormones are directly or indirectly involved in the pathogenesis of the OSCC and can be utilized in its management and prevention.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"30 1","pages":"154-159"},"PeriodicalIF":0.0,"publicationDate":"2017-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82402385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：